Latest Anthracyclines Stories
COLUMBIA, Md., Sept.
PRINCETON, N.J., Sept. 1 /PRNewswire/ -- Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.
COLUMBIA, Md., Aug.
PRINCETON, N.J., June 21 /PRNewswire/ -- Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc. (Nasdaq: CEPH).
PRINCETON, N.J., June 14 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.
COLUMBIA, Md., June 14 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that an abstract on the Phase I/II DIGNITY trial of ThermoDoxÂ® in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 52nd American Society for Radiation Oncology (ASTRO) Annual Meeting.
Encouraging trend observed in overall survival QUEBEC CITY, June 7 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
QUEBEC CITY, May 21 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
SEATTLE, May 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen.
SEATTLE, May 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.